R&D
Anticancer Drug/Personalized Anticancer Drug/Osteoarthritis/COPD/Neurodegenerative Diseases
-
01
Chronic Obstructive
Pulmonary Disease
(COPD)
-
COPD is a chronic life-threatening lung disease that causes obstructed airflow from
the lungs. The most common forms of COPD are chronic bronchitis and emphysema,
as well as refractory (non-reversible) asthma.
-
According to research and consulting firm GlobalData, "The chronic obstructive
pulmonary disease (COPD) space across the eight major markets... is set to rise
from $9.9 billion in 2015 to around $14.1 billion by 2025, representing a compound
annual growth rate of 3.7%."
-
Despite the increasing number of drugs available on the market,
COPD remains an incurable disease.
-
02
Therapeutics
Development
-
The regenerative effects of MSCDVs were observed in the damaged lungs of
the animal model of COPD. This study was conducted in collaboration with
Seoul Asan Medical Center.
-
Intratracheal administration presents a higher regenerative effect in lung cells at
a lower dosage compared to intravenous injections.
-
Based on these promising results, an Investigational New Drug (IND) application
for COPD will be submitted in 2022.